Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | JUN | P05412 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 3/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | PDXK | O00764 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30238970 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2TYRO3DYRK1B | |
| Formic Acid SCHEMBL29024515 | 0.90 | JUN (0.33) | NOS3NOS1NOS2TYRO3DYRK1B | |
| SCHEMBL6219173 | 0.83 | AURKA (0.34) | JUNNFKB1NFKB2RELAKDM4E | |
| SCHEMBL10523216 | 0.80 | JUN (0.41) | NOS3NOS1NOS2TYRO3DYRK1B | |
| SCHEMBL10520740 | 0.80 | NOS3 (0.39) | NOS3NOS1NOS2TYRO3DYRK1B | |
| SCHEMBL25147465 | 0.80 | DHFR (0.49) | NOS3NOS1NOS2DHFR | |
| SCHEMBL3705875 | 0.80 | LMNA (0.40) | NOS3NOS1NOS2NFKB1ALDH1A1 | |
| SCHEMBL30961287 | 0.79 | ALDH1A1 (0.31) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL25918302 | 0.79 | JUN (0.33) | NOS3NOS1NOS2TYRO3DYRK1B | |
| SCHEMBL4321200 | 0.79 | KMT2A (0.39) | TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4709381-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| EP-4674841-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025092905-A1 | PARP INHIBITORS AND USES THEREOF | SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025091346-A1 | PARP INHIBITORS AND USES THEREOF | SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| EP-1565467-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Proskelia SAS (FR) | 2005-08-24 | — | — | EP | disclosed |
| EP-1560829-A1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY (II) | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| EP-1560832-A1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | DERMATAKIS APOSTOLOS (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040110773-A1 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004041821-A1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY (II) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041822-A1 | PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | NOS3 3232/4885NOS1 2715/4885NOS2 2510/4885 |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FYN | NOS3 3685/4885NOS1 3727/4885NOS2 3735/4885 |
| US-20040110773-A1 | Pyrimido compounds having antiproliferative activity | SRC, LYN, TK1 | NOS3 3244/4885NOS1 3371/4885NOS2 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.